Commentary Open Access
Volume 1 | Issue 1 | DOI: https://doi.org/10.33696/Proteomics.1.001
A Bioinformatics Protocol for Rational Design of Peptide Vaccines and the COVID-19 Rampage
Ashesh Nandy1,*, Subhas C Basak2, Smarajit Manna1,3
- 1Centre for Interdisciplinary Research and Education, Kolkata 700068, INDIA
- 2Department of Chemistry and Biochemistry, University of Minnesota, Duluth, MN, USA
- 3Jagadis Bose National Science Talent Search, 1300 Rajdanga Main Road, Kolkata – 700107, INDIA
Corresponding Author
Ashesh Nandy, anandy43@yahoo.com
Received Date: July 21, 2020
Accepted Date: August 25, 2020
Nandy A, Basak SC, Manna S. A Bioinformatics Protocol for Rational Design of Peptide Vaccines and the COVID-19 Rampage. Arch Proteom and Bioinform. 2020; 1(1): 1-8.
Copyright: © 2020 Nandy A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Recent decades have witnessed the emergence of many viral diseases some of which have resulted in epidemics and global pandemics. Design of drugs and vaccines for such diseases is expensive and time consuming. In this article we propose a new computer-assisted method for the fast design of a new class of vaccines, the peptide vaccines, based on the genetic sequences of the pathogens. It is expected that this approach will assist in fighting emerging pathogens.
Keywords
Bioinformatics, Vaccines, COVID-19
Recommended Articles
A Bioinformatics Protocol for Rational Design of Peptide Vaccines and the COVID-19 Rampage
The currently ongoing coronavirus pandemic, the SARSCOV- 2, interchangeably referred to as the COVID-19 infection, has in a short span of time altered the ways and means of almost all of mankind. So strong has been its effect that all human activity ceased in one way or another for a considerable time, led to significant loss of life and economic drain of.
Dexamethasone: The First Drug to be Shown to Decrease Mortality in Critically Ill Patients with COVID-19
Background: The precise role of corticosteroids for treatment of coronavirus disease 2019 (COVID-19) is unclear due to lack of randomized trials. Objective: To review the therapeutic value of corticosteroids for treatment of hospitalized patients with COVID-19 with more emphasis on randomized trials. Methods: English literature search of electronic databases supplemented by manual search up to June 29, 2020. Search terms included corticosteroids, COVID-19, dexamethasone, methylprednisolone, hydrocortisone, mortality, safety. Randomized trials were the main focus of research, but observational studies were also reviewed.
How to Prevent Rehospitalization in Patients with COVID-19
Since December 2019, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) caused by 2019 Novel Coronavirus (2019-nCoV) has resulted in 89,000 cases of Corona Virus Disease 2019 (COVID-19), formerly known as Novel Coronavirus Pneumonia (NCP) in China, including 2,450 deaths.
Preparing for a More Public Health-Aware Practice of Medicine in Response to COVID-19
After one year in a pandemic, we mourn the loss of over half a million lives in the United States, and over four million worldwide, and remain concerned over the challenges facing the families of 35 million people in the United States, and 200 million worldwide, who have suffered from cases of COVID-19.
The Use of Hydroxychloroquine and Interferons for the Prophylaxis of COVID-19
At the beginning of Covid-19 pandemic, we proposed to use hydroxychloroquine (HCQ) and intranasal interferon (IFN) a-2b spray to prevent SARS-CoV-2. Since then, clinical trials testing these two drugs separately for the treatment and prophylaxis have been reported. A consensus is forming that HCQ and IFNs are not effective in treating severe Covid-19. However, the pathogenesis of Covid-19 suggests that early intervention could reduce the infection and prevent the progression from mild to severe Covid-19.